Glabellar Frown Lines Clinical Trial
Official title:
A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines Utilizing Optimized Algorithms With the Cryo-Touch III Device
myoscience Inc. (Redwood City, CA) has developed a device for a novel, minimally invasive facial rejuvenation procedure designed to soften hyperdynamic facial lines. The myoscience Cryo-Touch III device uses well-established principles of cryobiology to cause localized reduction in muscle activity resulting in a reversible reduction in facial animation and the appearance of facial lines. The device operates on well-established cryobiology principles; that localized exposure to controlled low temperature conditions can alter tissue function. The therapy treats targeted motor nerves with low temperatures via a cold probe in the form of an assembly of small diameter needles, creating a highly localized treatment zone around the probe. The thermal algorithm is designed to produce a reversible loss of nerve conduction resulting in a temporary decrease in muscle contractility. Prior studies of Cryo-Touch, Cryo-Touch II and Cryo-Touch III have provided strong evidence of effectiveness and safety for applications in this indication. The goal of the study described herein is to investigate optimized algorithms and ongoing safety and effectiveness.
The development of facial rhytids or wrinkles is a natural part of the aging process,
resulting from the thinning of the dermis and epidermis due to a loss of elastic fibers and
collagen and subcutaneous fat loss. Contributors to the formation of facial rhytids include
exposure to ultraviolet light (sunlight) and gravity, as well as habitual facial expressions
which cause lines to occur in specific facial regions as the skin loses elasticity. In some
cases, hyperdynamic activity of underlying facial muscles leads to the development of
furrows in the glabella and frontalis areas. Activity of the facial muscles causes
hyperdynamic lines independent of the aging process and this can also be undesirable.
With an aging population, the demand for facial rejuvenation techniques has increased. A
range of treatment options have been developed to provide reduction in facial lines,
including topical medications, neuromuscular inhibiting injections, laser treatments,
cosmetic fillers, and surgical facelifts. Those options targeted specifically at
hyperdynamic furrows include botulinum toxin injection, injectable fillers, and surgical
resection of facial muscles or division of motor nerves. Although botulinum toxin injections
have become a popular approach to reduction of glabellar lines by providing partial chemical
denervation of the glabellar muscle complex, safety concerns exist related to the use of
this toxin. Injectable fillers do not mitigate the underlying muscular activity which
produces the facial furrows. Surgical strategies are limited by the risks and complications
typically associated with surgery, including bleeding, bruising, scarring, and infection. A
non-surgical, minimally invasive approach to elimination of facial hyperdynamic lines which
avoids the use of chemical toxins is desirable.
myoscience Inc. (Redwood City, CA) has developed a device for a novel, minimally invasive
facial rejuvenation procedure designed to soften hyperdynamic facial lines. The myoscience
Cryo-Touch III device uses well-established principles of cryobiology to cause localized
reduction in muscle activity resulting in a reversible reduction in facial animation and the
appearance of facial lines. The device operates on well-established cryobiology principles;
that localized exposure to controlled low temperature conditions can alter tissue function.
The therapy treats targeted motor nerves with low temperatures via a cold probe in the form
of an assembly of small diameter needles, creating a highly localized treatment zone around
the probe. The thermal algorithm is designed to produce a reversible loss of nerve
conduction resulting in a temporary decrease in muscle contractility. Prior studies of
Cryo-Touch, Cryo-Touch II and Cryo-Touch III have provided strong evidence of effectiveness
and safety for applications in this indication. The goal of the study described herein is to
investigate optimized algorithms and ongoing safety and effectiveness.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02236312 -
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
|
Phase 2 | |
| Active, not recruiting |
NCT05565950 -
AI-09 In Subjects With Glabellar Lines, GL-101
|
Phase 1/Phase 2 | |
| Completed |
NCT00430963 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
| Recruiting |
NCT05083286 -
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
|
Early Phase 1 | |
| Completed |
NCT03687736 -
Subject Satisfaction With AbobutulinumtoxinA Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT04281745 -
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
|
Phase 4 | |
| Active, not recruiting |
NCT05623410 -
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 3 | |
| Active, not recruiting |
NCT03440671 -
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03736928 -
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
|
Phase 2 | |
| Completed |
NCT00777803 -
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
| Completed |
NCT00430586 -
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
|
Phase 2 | |
| Completed |
NCT04281095 -
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT05146999 -
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT02428608 -
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
|
Phase 2 | |
| Completed |
NCT04143815 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
|
Phase 2 | |
| Not yet recruiting |
NCT05305768 -
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
|
Early Phase 1 | |
| Completed |
NCT05364580 -
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05320393 -
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
|
Phase 2 | |
| Completed |
NCT02677805 -
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
|
Phase 3 | |
| Completed |
NCT01333397 -
Safety and Efficacy Study of Dysport RU and Glabellar Lines
|
Phase 2 |